CY1123932T1 - Δομες πολυειδικου αντισωματος - Google Patents

Δομες πολυειδικου αντισωματος

Info

Publication number
CY1123932T1
CY1123932T1 CY20211100214T CY211100214T CY1123932T1 CY 1123932 T1 CY1123932 T1 CY 1123932T1 CY 20211100214 T CY20211100214 T CY 20211100214T CY 211100214 T CY211100214 T CY 211100214T CY 1123932 T1 CY1123932 T1 CY 1123932T1
Authority
CY
Cyprus
Prior art keywords
polyspecific antibody
structures
vectors
chemical formula
polynucleotide sequences
Prior art date
Application number
CY20211100214T
Other languages
English (en)
Inventor
Pallavi BHATTA
Emma Dave
Sam Philip Heywood
David Paul Humphreys
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CY1123932T1 publication Critical patent/CY1123932T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Η παρούσα περιγραφή σχετίζεται με ένα μόριο πολυειδικού αντισώματος το οποίο περιλαμβάνει ή αποτελείται από: α) μια πολυπεπτιδική αλυσίδα του χημικού τύπου (I): VH-CH1-X-V1 και β) μια πολυπεπτιδική αλυσίδα του χημικού τύπου (II): VL-CL-Y-V2, και φαρμακευτικά σκευάσματα που το περιλαμβάνουν, για παράδειγμα για χρήση στη θεραπεία. Η περιγραφή παρέχει επίσης πολυνουκλεοτιδικές αλληλουχίες που κωδικοποιούν τα εν λόγω μόρια πολυειδικού αντισώματος, φορείς που περιλαμβάνουν τα πολυνουκλεοτίδια, και κύτταρα ξενιστές που περιλαμβάνουν τους εν λόγω φορείς και/ ή τις πολυνουκλεοτιδικές αλληλουχίες. Παρέχεται μια μέθοδος για έκφραση ενός μορίου πολυειδικού αντισώματος της παρούσας περιγραφής από ένα κύτταρο ξενιστή.
CY20211100214T 2014-06-25 2021-03-12 Δομες πολυειδικου αντισωματος CY1123932T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1411320.3A GB201411320D0 (en) 2014-06-25 2014-06-25 Antibody construct
PCT/EP2015/064409 WO2015197772A1 (en) 2014-06-25 2015-06-25 Multispecific antibody constructs
EP15732228.0A EP3161007B1 (en) 2014-06-25 2015-06-25 Multispecific antibody constructs

Publications (1)

Publication Number Publication Date
CY1123932T1 true CY1123932T1 (el) 2022-05-27

Family

ID=51410123

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191101082T CY1122175T1 (el) 2014-06-25 2019-10-15 Δομες πολυειδικου αντισωματος
CY20211100214T CY1123932T1 (el) 2014-06-25 2021-03-12 Δομες πολυειδικου αντισωματος

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20191101082T CY1122175T1 (el) 2014-06-25 2019-10-15 Δομες πολυειδικου αντισωματος

Country Status (27)

Country Link
US (2) US11345760B2 (el)
EP (2) EP3556777B1 (el)
JP (1) JP6765974B2 (el)
KR (1) KR102271204B1 (el)
CN (1) CN106459216B (el)
AU (2) AU2015279128B2 (el)
BR (1) BR112016027585A2 (el)
CA (1) CA2951609C (el)
CL (1) CL2016003324A1 (el)
CY (2) CY1122175T1 (el)
DK (2) DK3161007T3 (el)
ES (2) ES2866398T3 (el)
GB (1) GB201411320D0 (el)
HR (2) HRP20191775T1 (el)
HU (2) HUE046027T2 (el)
IL (1) IL249003B (el)
LT (2) LT3556777T (el)
ME (1) ME03539B (el)
MX (1) MX2016015952A (el)
MY (2) MY176332A (el)
PL (2) PL3556777T3 (el)
PT (2) PT3161007T (el)
RS (2) RS61493B1 (el)
RU (1) RU2725812C2 (el)
SG (2) SG10201911670QA (el)
SI (2) SI3556777T1 (el)
WO (1) WO2015197772A1 (el)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2729278T3 (es) * 2011-09-16 2019-10-31 Ucb Biopharma Sprl Anticuerpos neutralizantes de las exotoxinas principales tcda y tcdb de Clostridium difficile
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
CA3022494A1 (en) 2016-05-01 2017-11-09 Ucb Biopharma Sprl Affinity engineered serum protein carrier binding domain
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
KR20210078517A (ko) 2018-10-16 2021-06-28 유씨비 바이오파마 에스알엘 중증근무력증의 치료 방법
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
GB201906835D0 (en) 2019-05-15 2019-06-26 Ucb Biopharma Sprl Dry microparticles
BR112021021212A2 (pt) 2019-06-20 2021-12-28 UCB Biopharma SRL Detecção de agentes de floculação em uma amostra de proteína baseada em hplc
CN114401984A (zh) 2019-08-02 2022-04-26 Ucb生物制药有限责任公司 纯化抗体的方法
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
WO2021191424A1 (en) 2020-03-27 2021-09-30 UCB Biopharma SRL Autonomous knob domain peptides
WO2021224369A1 (en) 2020-05-08 2021-11-11 UCB Biopharma SRL Arrays and methods for identifying binding sites on a protein
GB202012991D0 (en) 2020-08-20 2020-10-07 Ucb Biopharma Sprl Cell culture processes
WO2022079036A1 (en) 2020-10-13 2022-04-21 Almirall, S.A. Bispecific molecules and methods of treatment using the same
IL301859A (en) 2020-10-15 2023-06-01 UCB Biopharma SRL Binding molecules for CD45 multimerization
US20230406924A1 (en) 2020-11-02 2023-12-21 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
GB202018889D0 (en) 2020-12-01 2021-01-13 UCB Biopharma SRL Formulations
CN116670166A (zh) 2020-12-07 2023-08-29 Ucb生物制药有限责任公司 多特异性抗体和抗体组合
KR20230118128A (ko) 2020-12-07 2023-08-10 유씨비 바이오파마 에스알엘 인터루킨-22에 대한 항체
WO2022167815A1 (en) 2021-02-04 2022-08-11 Rq Biotechnology Limited Antibodies
CA3211407A1 (en) * 2021-02-19 2022-08-25 Innovent Biologics (Suzhou) Co., Ltd. Anti-gprc5dxbcmaxcd3 trispecific antibody and use thereof
GB202103785D0 (en) 2021-03-18 2021-05-05 UCB Biopharma SRL Formulations
EP4067381A1 (en) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Novel tnfr2 binding molecules
GB202105424D0 (en) 2021-04-16 2021-06-02 UCB Biopharma SRL Cell culture processes
CN117642428A (zh) 2021-05-03 2024-03-01 Ucb生物制药有限责任公司 抗体
CA3218911A1 (en) 2021-05-10 2022-11-17 UCB Biopharma SRL Process for the production of recombinant proteins
GB202107153D0 (en) 2021-05-19 2021-06-30 UCB Biopharma SRL Method for filling vials containing liquid drug products
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
GB202115121D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202115127D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202115122D0 (en) 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
TW202334240A (zh) 2021-11-18 2023-09-01 比利時商Ｕｃｂ生物製藥公司 治療進行性慢性間質性肺部疾病之方法
GB202116665D0 (en) 2021-11-18 2022-01-05 UCB Biopharma SRL Method for the treatment of a scleroderma disease
GB202118010D0 (en) 2021-12-13 2022-01-26 UCB Biopharma SRL Method for detecting and/or quantifying crosslinks formed by transglutaminases
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
WO2023242238A1 (en) 2022-06-15 2023-12-21 UCB Biopharma SRL Cell culture processes
WO2024079114A1 (en) 2022-10-11 2024-04-18 UCB Biopharma SRL Process for the production of recombinant proteins

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1026240A3 (en) 1988-09-02 2004-04-07 Dyax Corp. Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
EP1231268B1 (en) 1994-01-31 2005-07-27 Trustees Of Boston University Polyclonal antibody libraries
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
WO1997038102A1 (en) 1996-04-04 1997-10-16 Unilever Plc Multivalent and multispecific antigen-binding protein
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
ES2234241T3 (es) 1998-01-23 2005-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Derivados de anticuerpo de multiples fines.
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6387981B1 (en) 1999-10-28 2002-05-14 3M Innovative Properties Company Radiopaque dental materials with nano-sized particles
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
IL151853A0 (en) 2000-04-11 2003-04-10 Genentech Inc Multivalent antibodies and uses therefor
WO2001090192A2 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
EP1294904A1 (en) * 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
JP2004523205A (ja) 2000-07-25 2004-08-05 イムノメディクス， インコーポレイテッド 多価標的結合タンパク質
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
CA2507004A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
DK1644412T4 (en) 2003-07-01 2018-11-12 Ucb Biopharma Sprl MODIFIED ANTIBODY-FAB FRAGMENTS
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009526857A (ja) 2006-02-15 2009-07-23 イムクローン・リミテッド・ライアビリティ・カンパニー 機能性抗体
SG170750A1 (en) 2006-03-17 2011-05-30 Biogen Idec Inc Stabilized polypeptide compositions
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
WO2008094708A2 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
EP2167130A2 (en) 2007-07-06 2010-03-31 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
CA2696263C (en) 2007-08-15 2017-06-13 Bing Liu Monospecific and multispecific antibodies and method of use
KR20100052545A (ko) 2007-08-28 2010-05-19 바이오겐 아이덱 엠에이 인코포레이티드 Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
AU2008328781A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
CN102643345A (zh) * 2008-09-26 2012-08-22 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
SI2334705T1 (sl) 2008-09-26 2017-05-31 Ucb Biopharma Sprl Biološki produkti
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
SG175081A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
BRPI1007602A2 (pt) 2009-05-27 2016-02-16 Hoffmann La Roche "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia"
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
BR112012028326A2 (pt) 2010-05-06 2017-03-21 Novartis Ag anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
EP2578230A1 (en) 2011-10-04 2013-04-10 Trion Pharma Gmbh Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
BR112014011304B1 (pt) * 2011-11-11 2022-03-03 UCB Biopharma SRL Anticorpos de ligação com albumina e fragmentos de ligação dos mesmos, proteína de fusão de anticorpo bi-específico, polinucleotídeo, célula hospedeira, processo de produção de anticorpo ou fragamento do mesmo, formulação farmacêutica e uso
WO2013163427A1 (en) * 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
WO2014054804A1 (ja) 2012-10-05 2014-04-10 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
AU2019205981B2 (en) 2020-05-28
MY176332A (en) 2020-07-29
EP3556777B1 (en) 2021-01-20
RU2020115720A3 (el) 2021-11-30
CY1122175T1 (el) 2020-11-25
AU2019205981A1 (en) 2019-08-01
KR20170020367A (ko) 2017-02-22
JP6765974B2 (ja) 2020-10-07
RS61493B1 (sr) 2021-03-31
EP3161007B1 (en) 2019-08-07
GB201411320D0 (en) 2014-08-06
EP3556777A1 (en) 2019-10-23
SI3556777T1 (sl) 2021-03-31
RU2017102193A (ru) 2018-07-25
US20170204200A1 (en) 2017-07-20
SG11201609678YA (en) 2016-12-29
JP2017520253A (ja) 2017-07-27
CL2016003324A1 (es) 2017-08-18
ES2750649T3 (es) 2020-03-26
LT3556777T (lt) 2021-04-12
EP3161007A1 (en) 2017-05-03
AU2015279128B2 (en) 2019-05-16
IL249003A0 (en) 2017-01-31
RS59416B1 (sr) 2019-11-29
PL3556777T3 (pl) 2021-07-12
IL249003B (en) 2019-09-26
BR112016027585A2 (pt) 2018-01-30
SI3161007T1 (sl) 2019-10-30
HUE046027T2 (hu) 2020-01-28
DK3161007T3 (da) 2019-10-14
RU2020115720A (ru) 2020-07-22
MY195318A (en) 2023-01-12
KR102271204B1 (ko) 2021-06-30
DK3556777T3 (da) 2021-04-12
PT3161007T (pt) 2019-10-25
WO2015197772A1 (en) 2015-12-30
ES2866398T3 (es) 2021-10-19
PT3556777T (pt) 2021-03-19
AU2015279128A1 (en) 2016-12-01
LT3161007T (lt) 2019-10-10
RU2017102193A3 (el) 2019-03-01
CN106459216A (zh) 2017-02-22
PL3161007T3 (pl) 2020-02-28
CN106459216B (zh) 2021-04-20
HRP20191775T1 (hr) 2019-12-27
US11345760B2 (en) 2022-05-31
MX2016015952A (es) 2017-04-05
HRP20210389T1 (hr) 2021-04-16
SG10201911670QA (en) 2020-02-27
RU2725812C2 (ru) 2020-07-06
HUE053457T2 (hu) 2021-06-28
US20220267476A1 (en) 2022-08-25
CA2951609A1 (en) 2015-12-30
ME03539B (me) 2020-07-20
CA2951609C (en) 2022-02-22

Similar Documents

Publication Publication Date Title
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
EA202090290A1 (ru) ПРИМЕНЕНИЕ БЕЛКА Cas, СПОСОБ ДЛЯ ОБНАРУЖЕНИЯ ЦЕЛЕВОЙ МОЛЕКУЛЫ НУКЛЕИНОВОЙ КИСЛОТЫ И НАБОР
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
BR112016030424A2 (pt) construções de anticorpo multiespecíficas
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
AR106201A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
BR112017006736A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização
EA201591814A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ Fc
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
AR105634A1 (es) Anticuerpos que se unen a il 8 y sus usos
UY37523A (es) Anticuerpos anti-ox40 y sus usos
PE20170704A1 (es) Agente terapeutico que induce citotoxicidad
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
EA201690529A1 (ru) Способы модификации клетки-хозяина
CO2017011238A2 (es) Anticuerpos anti-c1s humanizados
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
CL2016000438A1 (es) Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica
MX2019007248A (es) Enzimas de polimerizacion para reacciones de secuenciacion.
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
MX2018014366A (es) Interfaces de proteina.